Comparative efficacy of fluticasone furoate/umeclidinium/vilanterol(FF/UMEC/VI)versus budesonide/glycopyrrolate/formoterol fumarate(B/G/F) therapies in COPD patients

Comparative efficacy of fluticasone furoate/umeclidinium/vilanterol(FF/UMEC/VI)versus budesonide/glycopyrrolate/formoterol fumarate(B/G/F) therapies in COPD patients - Comparative efficacy of triple therapies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041089

Enrollment

Registered

2020-07-14

Start date

2019-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

fluticasone furoate/umeclidinium/vilanterol Budesonide Glycopyrronium Bromide Formoterol Fumarate Hydrate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inhalable COPD patients

Exclusion criteria

Exclusion criteria: patients with HOT

Design outcomes

Primary

Measure	Time frame
the efficacy of these inhalers after one month treatment	—

Secondary

Measure	Time frame
to identify the characteristics of the patients based on the efficacy with FF/UMEC/VI and B/G/F	—

Countries

Japan

Contacts

Public ContactNaoki Miyao

Nippon Koukan Hospital Pulmonary division

kengo-ootsuka@koukankai.or.jp0443335591

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026